Edwards Q1 sales $1.41B (+6.2%), TMTT surging 58%, guidance raised

Edwards Lifesciences Corp

2025-Q1 EPS reported $0.61 revenue$1,412,700,000

Q1 sales $1.41B (+6.2% reported, +7.9% adjusted); GAAP EPS $0.62, adjusted EPS $0.64.
TAVR sales $1.05B (+3.8%, +5.4% constant currency); TMTT sales $115M (+58%).
Gross margin 78.7%; operating margin 27.9% (adj. 29.1%) on favorable mix and delayed expenses.
2025 guidance: total sales raised to $5.7-6.1B; TMTT raised to $530-550M; adj. EPS reaffirmed $2.40-2.50.
Q2 guidance: sales $1.45-1.53B, adj. EPS $0.59-0.65; CE Mark SAPIEN M3, NCD for EVOQUE.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.